ATC Group: A04AA02 Granisetron

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A04AA02 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Antiemetics and antinauseants
3
Antiemetics and antinauseants
4
Serotonin (5HT3) antagonists
5
A04AA02
Granisetron

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
2 mg
PAREN - Parenteral
3 mg
T-DERMAL - Transdermal
3.1 mg

Active ingredients in A04AA02

Active Ingredient
Description

Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5HT3 receptors). Pharmacological studies have demonstrated that granisetron is effective against nausea and vomiting as a result of cytostatic therapy.

Medicines in this ATC group

Drug
Countries

Germany

Singapore

South Africa

New Zealand

South Africa

South Africa

Australia Austria Brazil Ecuador Estonia ...

Austria Estonia Finland Hong Kong Ireland ...

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)